• Zhengye Biotechnology regained compliance with Nasdaq’s $1 minimum bid-price rule, removing the risk of a delisting process tied to the deficiency.
• Nasdaq confirmed the shares closed at $1 or higher for 10 consecutive sessions from July 20 to Aug. 4, following a May 29 notice.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zhengye Biotechnology Holding Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608060800PRIMZONEFULLFEED9805088) on August 06, 2026, and is solely responsible for the information contained therein.